Tavilermide
Tavilermide is a pharmaceutical drug that was under development for the treatment of dry eye syndrome. It was developed by Mimetogen Pharmaceuticals, a company based in Montreal, Canada. The drug was designed to stimulate the production of mucin, a key component of the tear film, in the eye's surface cells. However, the development of Tavilermide was discontinued in 2018.
History[edit | edit source]
Tavilermide was initially developed by Mimetogen Pharmaceuticals, a company that specializes in the development of small molecule drugs. The drug was designed to stimulate the production of mucin in the eye's surface cells, which is a key component of the tear film. This was intended to help alleviate the symptoms of dry eye syndrome.
In 2013, Mimetogen entered into a licensing agreement with Allergan, a global pharmaceutical company, for the development and commercialization of Tavilermide. The drug entered Phase 3 clinical trials in 2015.
However, in 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials, which showed that the drug did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.
Mechanism of Action[edit | edit source]
Tavilermide is a small molecule that mimics the action of nerve growth factor (NGF). It works by binding to the TrkA receptor, which is found on the surface of cells in the eye. This stimulates the production of mucin, a key component of the tear film that helps to keep the eye moist.
Clinical Trials[edit | edit source]
Tavilermide entered Phase 3 clinical trials in 2015. The trials were designed to evaluate the safety and efficacy of the drug in patients with dry eye syndrome. However, the results of the trials showed that Tavilermide did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.
Discontinuation[edit | edit source]
In 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials. The company stated that it would continue to focus on its other ophthalmology products.
See Also[edit | edit source]
| Tavilermide Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
